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Abstract
Background
Treatment response to systemic corticosteroid in asthmatic children is heterogeneous and
may be mediated by epigenetic mechanism(s). We aim to identify DNA methylation (DNAm)
changes responsive to steroid, and DNAm biomarkers that distinguish treatment response.
Materials and methods
We followed 33 children (ages 5–18) presenting to the Emergency Department (ED) for
asthma exacerbation. Based on whether they met discharge criteria in24 hours, partici-
pants were grouped into good and poor responders to steroid treatment. Nasal samples
were collected upon presentation to the ED (T0) and 18–24 hours later (T1). Genome-wide
DNAm was measured for both time points in 20 subjects, and compared between T0 and T1
in good and poor responders respectively. DNAm at T1 was also compared between two
responder groups. DNAm of selected CpGs was verified in the complete cohort, and expres-
sion of associated genes was examined. Interactions between DNAm, common single
nucleotide polymorphism (SNP) located at the CpG sites and treatment responses were
assessed.
Results
Three CpGs located in the OTX2 promoter showed responder-specific DNAm changes from
T0 to T1, in which DNAm decreased in good but not in poor responders. Good and poor
responders showed differential DNAm at T1 in 127 CpGs without and 182 CpGs with com-
mon SNP co-localization. Negative correlations between DNAm and gene expression were
observed at CpGs located within the LDHC promoter, suggesting an impact of DNAm on
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gene regulation. Interactions between SNPs, DNAm and treatment response were
detected.
Conclusion
Acute systemic steroid treatment modifies nasal DNAm in good responders. Nasal DNAm,
dependent or independent of SNPs, can differentiate response to treatment in acute asth-
matic children.
Introduction
Asthma is the leading cause of emergency care and hospitalization in children. The current
standard and most effective treatment for treating asthma exacerbation is systemic corticoste-
roid treatment. However, due to heterogeneity in asthma phenotypes and natural history [1,
2], 40–70% of asthma treatment showed absent or incomplete efficacy [3]. Heterogeneous
responses to current standard treatment regimens have been observed in children hospitalized
for acute asthma exacerbations, and nearly two thirds of children who currently have asthma
reported at least one attack in the previous 12 months. One potential explanation could be the
suboptimal management of asthma in the childhood age group [4]. Care practices other than
the standard treatments may improve asthma management; however, effective predictions of
responses to standard treatments are needed in prior.
Biomarkers that may be associated with differential responses to asthma treatments have
been researched in children presenting to the ED and hospitalized for exacerbation. As asthma
symptoms and responses to the standard treatment can change from episode to episode in the
same person, biomarkers that are more dynamic have drawn attention such as gene expression
[5]. Recently, DNA methylation has been increasingly explored due to its important role in the
regulation of gene expression. DNA methylation (DNAm) is the modification of cytosine by
adding a methyl group to the 5’ position of C. DNAm mostly occurs in the context of CpG
dinucleotides and represents an important epigenetic mechanism that regulates gene expres-
sion [6]. Several studies have successfully identified DNAm of certain nucleotides as a bio-
marker for asthma [7–12], and suggested that nasal DNAm marks may be useful biomarkers
of disease severity and treatment response [12]. Efforts have also been made to identify DNAm
markers for asthma that develops in childhood and persists into early adulthood [13] and
markers for temporal asthma transition [14]. Interactions between CpG methylation and
genetic variation, especially single nucleotide polymorphisms (SNPs) located at C or G that
can disrupt or create a CpG site (meSNPs or CpG-SNPs), are prevalent in the human genome
(~15%) [15, 16]; such interactions have been associated with several diseases including child-
hood asthma [17–21]. In the present study, we examined genome-wide DNAm using nasal
epithelial cells to comprehensively search for CpG sites that undergo differential methylation
changes in response to systemic corticosteroid treatment in good and poor steroid responder
groups, as well as to identify biomarkers for treatment response. We further validated these
findings by bisulfite pyrosequencing of a larger population, followed by determination of the
impact of DNAm on candidate gene expression and the impact of common meSNPs on
DNAm. We also evaluated associations between DNAm-modifying meSNPs (known as meth-
ylation quantitative trait locus or meQTLs) and treatment response. Our results provide novel
epigenetic biomarkers for treatment response to systemic steroid in asthmatic children and
potential therapeutic targets for alternative asthma therapies.
DNA methylation variation and asthma treatment responses
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Materials and methods
Study population
This study was approved by the Institutional Review Board at Cincinnati Children’s Hospital
Medical Center (CCHMC # 2008–1384). Using inclusion and exclusion criteria previously
described [5], children aged 5–18 years who presented to the CCHMC ED with acute asthma
exacerbation and had an asthma diagnosis were recruited during March 2011-Oct 2014 and
written informed consents were obtained from parents or guardians of the minors. Informa-
tion collected includes demographics, environmental exposures, asthma trigger information,
and personal and family allergy and asthma symptom history. Parent(s)/legal authorized rep-
resentatives also provided current inhaled corticosteroid (ICS) controller medication (Asma-
nex1, Flovent1, Qvar1, Pulmicort1, Advair1, Dulera1, Symbicort1, etc.). Usage of nasal
steroids in the past 4 weeks was recorded. To assess baseline asthma symptom severity and
control, a respiratory symptom score was calculated (based on frequency of wheeze, cough,
shortness of breath, and chest tightness) [22] and the age-specific Asthma Control Test™
(ACT) score was collected [23]. Information regarding the hospital course was extracted from
medical charts. Enrolled patients were treated according to the CCHMC evidence-based treat-
ment protocol for inpatient asthma exacerbation and discharged as previously defined [5]. As
previously described [5], they were classified as good and poor responders based on the time
required for them to clinically improve to the point where they achieve discharge criteria
(>24hrs or24hrs).
Treatment protocol and definition of length of stay
Enrolled patients were treated according to the CCHMC evidence-based treatment protocol
for inpatient asthma exacerbation and discharged as previously defined [5]. Briefly, all patients
received 2mg/kg/day of prednisone while hospitalized and ICS were continued via mouth-
piece. Clinical discharge criteria were met when: (1) oxygen saturations were greater than or
equal to 91% on room air for at least 6 hours; (2) no evidence of respiratory distress; and (3)
reached a time point at which the patient demonstrated sufficient clinical improvement while
receiving albuterol no more frequently than every 4 hours for a period of 8 hours (q4h x 2).
Length of stay (LOS) was calculated as the time the disposition was set to admit to the time the
subject met the clinical criteria for discharge. Based on our previous data [5], good responders
were defined as those with LOS24 hours (short LOS) and poor responders as those with
LOS>24 hours (long LOS).
Nasal sample collection and DNA/RNA extraction
Nasal epithelial samples were collected at two time points from each subject: (1) upon presen-
tation to the ED (T0) and (2) on the inpatient floor 18–24 hours after receiving systemic corti-
costeroids in the ED (T1). Nasal mucosa sampling was performed with a CytoSoft Brush
(Medical Packaging Corp, CA, USA), and the samples were immediately taken to the labora-
tory for processing. Nasal samples collected contained>90% epithelial cells, similar to our pre-
vious findings [24]. DNA and RNA were extracted with the AllPrep DNA/RNA Micro kit
(Qiagen, Hilden, Germany), according to the manufacturer’s protocols.
Illumina 450K array processing
For genome wide DNAm assay, we used 40 samples from 20 subjects as the discovery popula-
tion. Genomic DNA from the nasal cells was bisulfite treated and assayed by the Illumina Infi-
nium HumanMethylation450 BeadChip (Illumina). Quality of the array was assessed using
DNA methylation variation and asthma treatment responses
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sample-independent and dependent internal control probes included on the array for staining,
extension, hybridization, specificity and bisulfite conversion. All the samples passed the QC
and were included in the discovery analysis. The signal intensities were then background-
adjusted using out-of-band probes (noob), and normalized using functional normalization
with R package “RnBeads”. Beta values were calculated as
signalmethylation
signal methylationþ signalunmethylation
and used in
further analyses. CpG sites that were not detected in all samples at p = 0.01 level, and CpG sites
on the X and Y chromosomes were excluded.
Array data have been deposited to NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) with
the accession number GSE104087.
450K array SNP annotation and GREAT annotation
To examine whether reported sites from Illumina 450K Arrays overlap with any known poly-
morphisms, common SNPs from dbSNP 142 table with minor allele frequency (MAF)1%
were extracted and used to annotate these sites. The majority of the reported array sites do not
contain strand-specific information and are CpG dinucleotides. These reported 1bp site along
with its consecutive downstream base were examined for overlapping with any known com-
mon SNPs. A small portion of the reported array sites have strand-specific information and
are non-CpG methylation sites (CHG, H = A, C, T). For these sites, only the reported 1bp site
was examined. When a site is found to be overlapping with polymorphisms, a binary indicator
along with allele information, rsID, and observed strand, are added to the reported array site
as annotations. In addition to the Illumina annotation for CpG sites on arrays, we also utilized
Genomic Regions Enrichment of Annotations Tool (GREAT) to search for genes in close
proximity with CpG sites [25].
Bisulfite pyrosequencing
For DNAm measurement, a total of 200ng genomic DNA was subjected to sodium bisulfite
treatment and purified using the EZ DNA methylation-Gold Kit (Zymo research, Irvine, CA,
USA) according to the manufacturer’s specifications. Pyrosequencing was carried out using
Pyro Gold reagents with a PyroMark vacuum prep workstation and a PyroMark Q96 MD
instrument (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. The gen-
erated pyrograms were automatically analyzed using Pyro Q-CpG methylation analysis soft-
ware (Qiagen, Valencia, CA, USA). 100% methylation control (SssI-treated human genomic
DNA) and 0% methylation control (human genomic DNA amplified by GenomePlex1 Com-
plete WGA kit (Sigma, St. Louis, MO, USA)) were used in validating all assays. For SNP analy-
sis, DNA was subjected to PCR amplification without bisulfite treatment. The allele frequency
of possible SNPs was calculated by the PyroMark MD 1.0 (Qiagen). Pyrosequencing assay
design and genomic coordinates are as documented in S1 Table.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was reverse-transcribed to cDNA using the Superscript III kit (Life Technologies,
NY, USA) using random hexamers according to manufacturer’s instructions. Real-time quan-
titative PCR was performed using the SYBR Green Master Kit and LightCycler1 480 instru-
ment (Roche Diagnostics, Indianapolis, IN, USA). PCR was carried out in triplicate from each
fraction and the mean Ct value of the triplicate reaction was normalized against the mean Ct
value of GAPDH. Primer sequences are described in S2 Table.
DNA methylation variation and asthma treatment responses
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Ingenuity pathway analysis
To better understand the biological meaning of the methylation changes, genes associated with
identified differentially methylated CpG sites were extracted from 450K array annotation file
and was imported into Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City,
CA) for pathway mapping, gene network detection, and upstream regulator identification. A
cutoff of 0.05 was used for statistical significance in IPA analysis.
Statistical analysis
The analyses were performed as outlined in Fig 1. To identify CpG sites with responder-spe-
cific T0-T1 changes, the association between DNAm (beta value from the array; see detailed
description in the supplementary information) and time were tested using linear regression in
poor and good responders respectively. To identify CpG sites with differential DNAm between
poor and good responders, we tested the association between beta value and responder status
with linear regression using data from T1. Age, gender, and race (dichotomized as black and
Fig 1. Analysis flowchart.
https://doi.org/10.1371/journal.pone.0186150.g001
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non-black) were adjusted. To further correct for the batch effect and bias caused by unknown
confounders such as cell composition, we performed surrogate variable analysis (SVA) using
the R package “SVA”. Three significant SVs were detected. The associations described above
were then tested again with three SVs being included in the modeling. Only CpG sites identi-
fied in both sets of analyses were selected for further examination. For array analysis, nominal
significance was defined as p value0.05, and genome-wide significance was defined as q
value0.05 [26].
To verify the CpG sites identified from the array that showed responder-specific T0-T1
changes in DNAm, we assayed 33 pairs of samples with bisulfite pyrosequencing and calcu-
lated the percent of methylation. As T0 and T1 DNAm are paired by subjects, to better account
for between-subject random effects, we used mixed models, in which a respondertime inter-
action was tested. Mixed models were also utilized to verify the CpG sites whose T1 DNAm
showed association with response to treatment. In these verification analyses, both T0 and T1
data were used with correlations between T0 and T1 being considered. We also calculated an
M value as M ¼ log2
methylation %
1  methylation %, which was examined to ensure the validity of conclusions
from models using beta values.
To determine genetic effects on DNAm, we clustered the beta values into full-, semi- and
non-methylated groups by examining the distribution of the beta values. The methylation
groups were then compared with the genotypes. To test the genetic association with the
responder status, we used an additive model in which genotypes were numerically coded
according to the number of minor allele. The genetic association was then tested using a logis-
tic model.
To assess the relationship between gene expression and DNAm, we used the Spearman cor-
relation. We also examined the association of LDHC expression with response to treatment,
and the responder-specific changes between T0 and T1 in OTX2 expression. As the expression
data exhibited log-normal distribution, the associations were tested using generalized estimat-
ing equation assuming a log-normal distribution of the data. Verification analyses were con-
ducted using SAS 9.4 unless otherwise specified. P values 0.05 were designated statistically
significant.
Results
Study overview and population characteristics
Our discovery population consisted of 20 exacerbating asthmatics who were not exposed to
nasal steroid within the past 14 days (S3 Table). To identify CpG sites whose DNAm status
was associated with systemic corticosteroid treatment response, we assayed the genome-wide
nasal methylation using paired DNA samples collected at both T0 and T1 from these 20
patients (40 samples total). As false positive results would occur even after stringent QC, data
preprocessing, and complex analyses of 450K arrays, we further verified significant associa-
tions using bisulfite pyrosequencing in the complete cohort.
The discovery population was composed of 60% black males, and 45% were good respond-
ers. There were no statistically significant differences in age, sex, race or number of good or
poor responders between the discovery population and the 13 additional subjects (S3 Table).
Among the 13 additional subjects, 7 of them reported previous exposure to nasal steroid (S3
Table). Therefore, the DNAm data at T0 of these 7 subjects measured by bisulfite pyrosequen-
cing were excluded from the analyses when T0 samples were studied. Mean baseline respira-
tory symptom frequency score and ACT scores were also comparable. When comparing good
and poor responders in the complete cohort, we found that most of the demographics and
clinical features were also similar (Table 1). While the poor responders had a slightly higher
DNA methylation variation and asthma treatment responses
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mean ACT (17.3 vs. 14.6, p = 0.047), the means of both groups are<19, indicating poor
asthma control. Overall there were no major differences between the populations.
Systemic steroid treatment significantly altered the nasal methylome
within 24 hours in good responders, but not in poor responders
Using the array data, we compared the methylation level for each CpG site between T0 and T1
in good and poor responders respectively. In poor responders, no CpG sites had changes in
methylation between T0 and T1 even at nominal level. In contrast, in the good responders, 5
CpG sites were identified whose methylation were significantly altered between T0 and T1 at
nominal level, but did not reach genome-wide significance (p0.05, absolute deltaBeta0.10,
S4 Table). Interestingly, 3 of the 5 CpG sites are in the promoter (defined as 2kb upstream
TSS) and 5’ UTR of OTX2, suggesting a possible regulatory role for these CpG sites. As two of
the three OTX2 CpGs are adjacently located, we were able to assay them and two additional
CpGs in the same region using one bisulfite pyrosequencing reaction (S1 Table). In all 4 CpG
sites, significant respondertime interactions were found (Fig 2). These results confirmed that
changes in DNAm from T0 to T1 differed by response status. Specifically, in good responders,
DNAm levels of CpG1-4 in the OTX2 promoter were significantly lower at T1, while in poor
responders, the DNAm level at T1 was comparable to T0 (CpG1-3) or elevated (CpG4).
DNAm in nasal cells separates poor responders from good responders
To identify markers that distinguish poor from good responders in the discovery phase, we
focused on samples collected at the T1 time point. In the verification phase, T0 samples that
had base line nasal steroid usage were excluded. Using the discovery array data of the T1 sam-
ples (Fig 1), at nominal level, we identified 309 autosomal CpG sites with differential DNAm
between the good and poor responders. Because SNPs can modify DNAm in cis, we further
removed CpGs whose DNAm might be subject to genetic influences. Among these CpG sites,
127 have no reported common SNPs at the C or G, but 42 of these 127 sites have reported
SNPs present on the array probes (<10bp away from the given CpG site) thus their DNAm
measurements may not be accurate due to the influences of the SNPs (Fig 1). After removing
these 42 sites, the remaining 85 sites could distinguish the two responder groups using hierar-
chical clustering (Ward’s minimum variance method in JMP). We then examined the distribu-
tion of the array data for these 85 sites, as well as the biological functions of genes near these
CpG sites. This process resulted in 32 CpG sites whose DNAm levels were sufficient to
Table 1. Demographics and clinical features of good and poor responders.
Good responders (N = 15) Poor responders (N = 18) p-value
Age 8.0 (6.0–14.0) 6.5 (5.0–11.0) 0.31
Male Sex 10 (67%) 12 (67%) 1.00
Race
White 2 (13%) 4 (22%) 0.86
Black 12 (80%) 12 (67%)
Biracial 1 (7%) 2 (11%)
Exposed to nasal steroid 4 (27%) 3 (17%) 0.67
Respiratory symptom score 2.0 (1.1) 2.5 (1.1) 0.19
ACT Score 14.6 (3.5) 17.3 (3.7) 0.047
Note: age was shown as median (IQR) and tested using Wilcoxon rank sum test; respiratory symptom and asthma control scores were shown as mean
(SD) and tested using t tests; the rest of the variables were shown as n (%) and tested using Fisher’s exact tests.
https://doi.org/10.1371/journal.pone.0186150.t001
DNA methylation variation and asthma treatment responses
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Fig 2. Promoter methylation of OTX2 showed differential changes in response to steroid treatment between good and poor
responders. The association of DNAm at 4 CpG sites located within the promoter region of OTX2 with time (T0 vs. T1) and responder
status were tested using mixed models with age, sex and race being adjusted. Data shown were least square means with standard
errors of the methylation% at T0 and T1 for good and poor responders respectively. P values were for the responder-specific T1-T0
changes.
https://doi.org/10.1371/journal.pone.0186150.g002
DNA methylation variation and asthma treatment responses
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completely separate the two responder groups (Fig 3A and S5 Table), and none of them were
measured by cross-reactive probes [27]. Two CpG sites (cg17187762 and cg00802903) that
reached genome-wide significance (q value <0.05, with and without SV) were included in
these 32 sites.
IPA pathway analysis of the genes implicated by these 32 CpG sites identified one network
that is over represented by the genes close to the 32 CpG sites (Fig 3B). Among genes in this
network, LDHC, Dynein heavy chain domain 1 (DNHD1), and proline-rich coiled-coil 1
(PRRC1) were chosen for verification. LDHC encodes lactate dehydrogenase and is highly
expressed in asthmatics. Its level in sputum has been established as a diagnostic marker for
asthma [28, 29]. DNHD1 encodes Dynein Heavy Chain Domain 1, which is a protein complex
that is involved in microtubule movement and expressed in the lung. DNAm at multiple CpG
sites within this gene, including the one identified from our study (cg10208301), is associated
with multiple sclerosis in blood DNA [30]. The proline-rich coiled-coil 1 protein encoded by
PRRC1 is highly expressed in oral epithelium and moderately expressed in lung tissues. Three
CpG sites within the gene body of DNHD1 (including cg10208301), three CpG sites within the
promoter of LDHC (including cg11821245), and three CpG sites within the promoter of
PRRC1 (including cg02762363 and cg04431054) were measured by bisulfite pyrosequencing in
both T0 and T1 samples from all 33 participants and their association with length of stay was
examined. As shown in Table 2, none of the sites showed differences in DNAm between T0
and T1, therefore data from T1 and T0 were combined and compared between good and poor
responders. Using this approach, all CpG sites identified by the arrays were verified, in which
good responders exhibited lower methylation compared to poor responders (Table 2). In
Fig 3. DNAm at 32 non-SNP CpG sites separate two responder groups. A. Hierarchical clustering of participants based on DNAm (Ward’s minimum
variance method, JMP). Yellow line represents the complete separation between good (top panel) and poor responders (bottom panel). B. Overrepresented
network from IPA analysis. CpG sites located close to genes circled in red were selected for verification.
https://doi.org/10.1371/journal.pone.0186150.g003
DNA methylation variation and asthma treatment responses
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addition, two CpG sites in LDHC that were not evaluated by the array also exhibited significant
differences between good and poor responders. Therefore, we identified novel epigenetic bio-
markers that may not be sensitive to the steroid treatment, but can differentiate poor respond-
ers from good responders.
DNAm levels in candidate genes correlate with gene expression
To assess the role of DNAm in the regulation of gene expression, we assayed the expression
levels of OTX2, LDHC, DNHD1, and PRRC1 in the same samples where DNAm levels were
measured. In OTX2, moderate negative correlation was detected between expression and
DNAm but did not reach statistical significance (Spearman r = -0.3 for all sites, p value ranging
from 0.08–0.12, S1A Fig). In LDHC, we observed strong negative correlation between expres-
sion and DNAm of all three CpG sites (Fig 4A, Spearman r ranging -0.6−-0.5, p<0.01 for all
sites). No significant negative correlations between expression and DNAm were found for
DNHD1 and PRRC1 (data not shown). Moreover, significant association between LDHC
expression and response to treatment was detected (Fig 4B, p = 0.016). Consistent with their
lower promoter DNAm in LDHC, good responders showed higher LDHC expression, support-
ing the down-regulation of LDHC expression by promoter DNAm. In OTX2, responder-spe-
cific T1-T0 changes in expression was suggested, but did not reach statistical significance (S1B
Fig, p = 0.06). In conclusion, we observed negative correlation between promoter DNAm and
expression for LDHC and OTX2, but not for DNHD1 and PRRC1.
Genetic variation modifies DNAm and associates with treatment
response
Among the 309 sites whose DNAm levels were associated with length of stay and therefore dif-
ferentiated poor responders from good responders, 182 had SNPs located at C or G according
to the 1000 genomes project (S6 Table). Such SNPs have the ability to disrupt or create a CpG
dinucleotide and thereby substantially modify DNAm. To examine the potential effects of
SNPs on DNAm, we visualized the distribution of DNAm levels by genotypes of 7 SNPs. At six
sites, a tri-modal distribution of DNAm was observed which completely aligned with the geno-
types (Table 3). Given the significant associations between DNAm and treatment response
and the good alignment between DNAm and genotypes, it is not surprising that in the 20 sub-
jects who had 450K array data, all the sites showed statistically significant or marginally
Table 2. CpG sites whose DNAm levels at T1 are associated with treatment response.
Gene site Target ID T1 T0 T1 + T0
poor good p-value poor good p-value poor good p-value
DNHD1 CG1 cg10208301 92.7±4.2 83.3±4.8 0.13 93.7±3.4 83.9±3.9 0.06 93.1±2.3 84.0±2.7 0.011
CG2 84.0±3.8 76.1±4.1 0.17 85.8±2.8 80.1±3.3 0.20 85.3±2.1 79.6±2.3 0.08
CG3 90.5±5.3 81.0±6.1 0.22 89.5±3.6 87.7±4.1 0.73 89.0±2.8 87.0±3.2 0.64
LDHC CG1 81.0±3.8 72.1±4.3 0.11 87.7±2.1 78.6±2.4 0.007 85.5±1.8 77.3±2.1 0.004
CG2 74.9±4.3 61.8±4.9 0.040 79.3±3.8 70.2±4.3 0.11 77.3±2.6 67.5±2.9 0.012
CG3 cg14332815 67.6±4.2 53.8±4.8 0.028 67.5±4.7 57.6±5.4 0.16 67.4±2.6 55.8±3.0 0.004
PRRC1 CG1 37.8±3.8 32.0±4.3 0.30 32.8±4.5 41.0±5.1 0.21 35.0±3.0 36.2±3.4 0.76
CG2 cg02762363 26.0±2.2 19.7±2.5 0.05 28.4±5.1 22.2±5.7 0.40 27.1±2.4 20.4±2.7 0.06
CG3 cg04431054 32.7±2.5 24.5±2.8 0.026 38.8±4.8 27.4±5.5 0.11 34.5±2.6 24.9±2.9 0.014
Note: DNAm were compared between good and poor responders using mixed models with age, sex and race being adjusted. Data shown were least square
means and standard errors.
https://doi.org/10.1371/journal.pone.0186150.t002
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significant genetic associations with responder status. For example, rs12282251 (C/T) is
located at the C position of cg16827215. The methylation levels at cg16827215 were completely
aligned with the genotypes (Fig 5A), with CC (red dots) showing complete methylation and
CT (blue dots) showing semi-methylation. Association of cg16827215 DNAm and genetic
association of rs12282251 with the responder status were also detected (Fig 5B and Table 3).
When all 33 genotyped subjects were analyzed using additive models, similar genetic associa-
tions were observed (Table 3); significant associations remained for four sites (rs12282251,
rs66630638, rs73006518 and rs76828276) while the other two (rs34756202 and rs73006518)
showed marginal significance. For rs75428195, although there is reported G/C variation in the
general population, we did not detect the C allele in our cohort, and all subjects had a GG
genotype. Therefore, the observed full and semi-methylation at cg05740244 (Fig 5D and 5E)
was not due to genetic variation, and responder status was only associated with methylation
levels, but not genotypes (Fig 5D and S7 Table). Moreover, similar to sites shown in Table 2,
these two sites also exhibited good DNAm agreement between T0 and T1 (Fig 5C and 5E). As
Fig 4. Relationships between LDHC expression, DNAm and treatment response. A. Correlations between LDHC expression
and DNAm at each of the three CpG sites. Paired methylation% and expression values were plotted for each sample as dots; the
regression lines showed negative correlation between expression and DNAm. B. Differential LDHC expression between good and
poor responders. The expression data were plotted as dots; the least square mean of each group was shown as solid triangle
along with 95% confidence limits.
https://doi.org/10.1371/journal.pone.0186150.g004
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T0 samples are not always available, our results therefore implicate the potential usage of T1
DNAm as a marker to differentiate good from poor responders.
Discussion
In this pilot study, we utilized a genome-wide approach to first search for CpG sites whose
DNAm levels respond to steroid treatment for asthma exacerbation in nasal epithelial cells.
We found that the promoter of OTX2 showed significantly decreased methylation after treat-
ment, but such decrease was only observed in children who responded well, not in children
who responded poorly. Using the same data, we also identified a novel set of CpG sites whose
methylation are unresponsive to treatment, yet distinguish the poor responders from the good
responders. Interestingly, quite a few of these CpG sites can be disrupted by the presence of
certain common SNPs; in most of these sites, DNA methylation was altered along with their
genotypes. Taken together, our findings suggest that epigenetic mechanisms underlie the het-
erogeneous responses to systemic steroid treatment, in part driven by genetic variations pres-
ent at CpG sites.
The OTX2 gene encodes a transcription factor with key roles in the brain [31, 32], craniofa-
cial and sensory organs [33, 34] and pituitary development [35]. Upon differentiation of plu-
ripotent stem cells, it also interacts with Oct4 to activate gene enhancers by establishing and
maintaining local active chromatin [36]. The role of OTX2 in asthma and response to steroid
treatment is unknown. Interestingly, Otx2 can directly interact with Foxa2 [37, 38], and such
interactions can be detected in vivo and govern development of the anterior mesendoderm,
node, and midline in mice [38]. Foxa2 has been implicated in suppression of goblet cell meta-
plasia during allergen challenge [39]. It suppresses the production of IL13, IL33, CCL20 and
CCL17 from airway epithelial cells and inhibits allergen-induced goblet cell differentiation
Table 3. Associations between DNAm, genotypes at meSNPs, and treatment response.
rsID cg Genotype
(n)
beta at T1
(SD)
%Poor
responders
Genetic association
(p value)
Chr location MA (%)
(ED)
MA (%)
(UCSC
hg19)
Putative
function
rs12282251 cg16827215 CC (20) 0.76 (0.06) 75% 0.003 11 11292635 T
(0.20)
T (0.18) 3’ UTR
CT (13) 0.43 (0.03) 23%
rs34756202 cg01882774 CC (17) 0.83 (0.03) 35% 0.11 14 94491763 T
(0.30)
T (0.26) Intron/
upstreamCT (12) 0.50 (0.10) 83%
TT (4) 0.07 (0.03) 50%
rs7933565 cg19680693 GG (12) 0.83 (0.04) 42% 0.10 11 94111808 A
(0.45)
A (0.53) 3’ UTR
GA (12) 0.52 (0.07) 50%
AA (9) 0.11 (0.05) 78%
rs66630638 cg08891829 GG (22) 0.93 (0.01) 36% 0.002 4 56231728 A
(0.16)
A (0.14) intron
AG (10) 0.52 (0.05) 90%
AA (1) 0.04 (-) 100%
rs73006518 cg22843488 CC (22) 0.90 (0.02) 41% 0.015 3 151017685 T
(0.19)
T (0.06) intron
CT (9) 0.67 (0.10) 78%
TT (2) 0.13 (0.02) 100%
rs76828276 cg05187322 CC (24) 0.90 (0.02) 42% 0.010 17 78152328 T
(0.12)
T (0.07) 5’ UTR
CT (9) 0.49 (0.04) 89%
Note: Minor allele and frequencies from current ED study and UCSC (hg19) were listed. For the genetic association tests, additive models were used. No
effects of age, sex or race on the responder status were detected.
https://doi.org/10.1371/journal.pone.0186150.t003
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[40], through reprogramming of Th2-mediated inflammation and innate immunity. Whether
OTX2 has similar roles in response to allergen warrants further mechanistic studies. We also
found no dexamethasone responsive elements or GR binding sites within 5000 bases of OTX2
in A549 cells treated with dexamethasone in a publically available GR ChIP-seq dataset [41].
No significant changes in expression or methylation of OTX2 were detected after dexametha-
sone treatment (24hrs) in human bronchial airway epithelial cells (data not shown). However,
in nasal samples from children, as opposed to poor responders who showed no significant
changes in DNAm and expression of OTX2, good responders showed decreased promoter
methylation after steroid treatment (Fig 2) and a trend of increase in expression (S1 Fig).
We have also identified 309 CpG sites whose DNAm levels were associated with treatment
response—182 overlap with common SNPs and 127 do not have SNP co-localization. Out of
Fig 5. Relationships between DNAm, genotype at meSNPs and treatment response. A-B. Relationship between rs12282251, cg16827215 and
treatment response. Red and blue dots represented the CC and CT genotypes, respectively. C. Good agreement of DNAm at cg16827215 between T0
and T1. D. DNAm at cg05740244 between good and poor responders. All participants have the same genotype (GG). E. Good agreement of DNAm at
cg05740244 between T0 and T1. Identity lines were drawn in C and E.
https://doi.org/10.1371/journal.pone.0186150.g005
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the CpGs without common SNP co-localization, we followed up on sites located at LDHC,
DNHD1 and PRRC1, and verified the associations of their DNAm with the treatment response.
Moreover, we also detected significant differential expression between the two responder
groups in LDHC (Fig 4B). The level of lactate dehydrogenase level in sputum has been estab-
lished as a diagnostic marker for asthma [28, 29], and our data suggest that it might also be a
useful marker for steroid treatment response. Among all verified sites, no CpG sites were
found to be strongly associated with poorly controlled asthma (ACT score), or base line
asthma symptom scores.
Out of the 182 SNP-containing sites, we genotyped 7 and found complete agreement
between genotypes and DNAm levels at 6 sites (Table 3). Furthermore, four sites showed sta-
tistically significant genetic association with the treatment response. These four sites are
located within GALNTL4 (or GALNT18, Polypeptide N-Acetylgalactosaminyltransferase 18),
SRD5A3 (Steroid 5 Alpha-Reductase 3), MED12L-GPR87 locus (mediator complex subunit
12-like and G protein-coupled receptor 87) and CARD14 (Caspase Recruitment Domain Fam-
ily Member 14). GALNTL4 encodes a glycosyltransferase that participates in the initial steps of
protein O-glycosylation and it is involved in the biosynthesis of simple mucin-type carbohy-
drate antigens and responsive to bacterial infection in mice gastric mucosa [42]. SRD5A3
encodes steroid 5-alpha reductase, plays a key role in the early steps of protein N-linked glyco-
sylation [43] and is required for the production of 5-alpha-dihydrotestosterone (DHT) from
testosterone in hormone-refractory prostate cancer [44]. rs73006518 is located within two pro-
tein coding genes, MED12L on the + strand and GPR87 on the—strand. The protein encoded
by MED12L exhibits sequence similarity with components of the Mediator complex and may
be involved in gene transcription. The G protein receptor encoded by GPR87 is a receptor for
lysophosphatidic acid (LPA) [45], and LPA may contribute to asthma by regulation of cytokine
synthesis and chemotaxis in lymphocytes [46–49], contractility and proliferation of smooth
muscle cells [50], and inflammatory signaling in airway epithelium [51]. LPA is also required
for p53-dependent cell survival in response to DNA damage [52] and its overexpression leads
to lung tumor cell proliferation [53]. The protein encoded by CARD14 belongs to the mem-
brane associated guanylate kinase (MAGUK) family, and may function as an upstream activa-
tor of BCL10 and NF-kappaB signaling and contribute to apoptosis [54]. Its expression in
bronchial airway epithelial cell was associated with exhaled nitric oxide in severe asthmatics
[55]. Although these studies support the biological functions of these genes in asthma pheno-
types, the potential utilization of these biomarkers to sufficiently predict future treatment
response in children hospitalized for asthma exacerbation awaits further evaluation in longitu-
dinal studies studying a large number of children in multiple hospitalizations. Once estab-
lished, these biomarkers will inform clinicians about a patient’s treatment response to steroid
during future asthma attacks and identify those who will be in need of alternative individual-
ized asthma management plan. This would significantly reduce length of hospitalization and
improve patient care.
It is intriguing that the genotype at C or G sites can modify DNAm levels in cis in airway
epithelial cells, and when C is present, it is always methylated. This indicates the complete
dependence of DNAm on genetic sequence at these locations, and is consistent with previous
reports that in CD4+ T cells over 80% of meSNPs are meQTLs [16]. The dictation of DNAm
by so-called small methylation determining regions has been observed during stem cell differ-
entiation [56]. Our findings also indicate that DNAm and genotypes can infer each other very
well at some genomic locations (6 out of 7 that we genotyped). Though it is difficult to tease
out which is truly the determinant for phenotype in our association study, because of its role
in gene expression regulation, DNAm becomes an intriguing explanation for the biological
effects of these genetic variants, especially those located in regulatory regions. Detailed
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mechanisms accounting for such tight regulation of DNAm by meSNPs warrants further
investigation. In addition, we also found one case where genotype did not completely follow
levels of DNAm. Therefore, genetic and epigenetic studies in the same population are both
required to fully understand the interplay between these two mechanisms and their collabora-
tive contribution to biological and pathological processes.
Conclusions
Despite small sample size, our research showed that DNAm variations can differentiate good
responders and poor responders. These epigenetic biomarkers may be used to distinguish chil-
dren who do not respond to steroid treatment well, therefore are in need of alternative novel
therapies. Further replication studies in children will be needed to substantiate these finding,
and the establishment of such biomarkers of treatment response will inform personalized
management plan during severe pediatric asthma exacerbations. DNAm biomarkers are more
interactive with environment, especially those independent of genetics. They reflect real time
dynamics of a patient, thus may better predict responses to asthma treatment from episode to
episode. Our findings in the genetic-dependent DNAm variation provide new insights for phe-
notypic variations associated with genetics. Besides being used as biomarkers, DNAm can also
be targets for future novel alternative therapies.
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